Skip to main content
AMAN logo

AMAN · Amanat Acquisition Corp.

Track AMAN — free
$10.10 +0.03 (+0.30%) At close · Nov 19
Market Cap
$97.72M
Shares
9.68M
Volume · Nov 19 51.73K Avg daily vol (3M) 63.59K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.10 Open$10.07 Day$10.06–10.11 Available close range$10.01–10.77 Avg vol 30d118K Short int42K · 0.4% of shares · 1.0d Short vol3% DataMay 2026–Nov 2026 Filing10-Q · Nov 13

The closing range uses available history since May 19, 2026; less than a full year is stored.

Latest documents

2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Corxel combination expected to close in first half of 2027

Amanat Acquisition Corp. agreed to combine with Corxel Pharmaceuticals, with closing expected in the first half of 2027. Management reported a $1,510,880 net loss from January 13, 2026 through September 30, 2026 and substantial doubt about its ability to continue as a going concern.

Net loss $1.48M
Read from the MD&A section
5 source passages
References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Amanat Acquisition Corp. On October 25, 2026, we, Cairo Merger Sub, Inc., a Delaware corporation and our wholly-owned subsidiary (“Merger Sub”), Corxel Pharmaceuticals, Inc., a Delaware corporation (“Corxel”), and Corxel Pharmaceuticals Limited, a Cayman Islands exempted company and the sole stockholder of Corxel (“Parent”), entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”). The business combination is expected to close in the first half of 2027, following the receipt of the requisite approvals of the Company’s shareholders and Corxel’s sole stockholder and the fulfillment of other customary closing conditions, including the expiration or termination of the applicable waiting period under the HSR Act. For the period from January 13, 2026 (inception) through September 30, 2026, we had net loss of $1,510,880, which consisted of formation, general and administrative costs of $2,376,371 and share-based compensation expense of $164,340, offset by change in fair value of over-allotment option liability of $58,600 and interest earned on investments held in the Trust Account of $971,231. These conditions raise substantial doubt about our ability to continue as a going concern. Open the document at this passage
Oct 26
Current report 8-K Events of Oct 25
Business combination with Corxel Pharmaceuticals at $200,000,000 equity value

On October 25, 2026, Amanat Acquisition Corp agreed to a business combination with Corxel Pharmaceuticals, based on an implied Corxel equity value of $200,000,000. The combination is expected to close in the first half of 2027, following approvals by Amanat's shareholders and Corxel's sole stockholder. The PIPE Financing carries aggregate purchase commitments of $300 million, subject to reduction mechanisms.

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure Read from the first part of this long document
5 source passages
On October 25, 2026, Amanat Acquisition Corp, a Cayman Islands exempted company which is based on an implied Corxel equity value of $200,000,000 The Business Combination is expected to close in the first half of 2027 following the receipt of the requisite approvals of AMAN’s shareholders and Corxel’s sole stockholder aggregate purchase commitments of $300 million, as adjusted for reduction mechanisms provided therein Open the document at this passage
May 27
Current report 8-K Events of May 20
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.08M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.4%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Limited Quant / Vol Very Low
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 50-day avg −3%
below
RSI (14) 30
neutral
MACD trend Positive
52-week position 12%
near low
Momentum
relative strength
Strong
1-month return −1%
trailing
6-month return 0%
trailing
Relative strength +5%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-8% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.43% of shares out · ▲ +1724.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
24 holders — 13F breadth
Squeeze score 45
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very Low
Volatility 7%
annualized · 1-yr
Max drawdown −7%
past year
ATR 0.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−3% Neutral
RSI (14)
30 Neutral
MACD trend
Positive Bullish
52-week position
12% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-8% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.43% of shares out · ▲ +1724.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
24 holders — 13F breadth
Price context
position in its available closing range
Range low $10 Now $10 · 12% Range high $11
vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Shell Companies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AMAN
Amanat Acquisition Corp.
this stock
$97.72M — — — 0.4%
VYLR
Vylor Inc.
$45.22B — — — 2.1%
CLUS
Cluster Group Holdings Ltd Co
$8.00B — — — —
DMII
Drugs Made In America Acquisition II Corp.
$652.92M +3.5% — — 0.2%
BCSS
Bain Capital GSS Investment Corp.
$607.94M +3.3% — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
24
% held
67.1%
Net QoQ
-69.8K sh
Top holder
Nantahala Capital Managem…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
41.8K
Days to cover
1.0d
Change
+39.5K sh
View
Short Volume
Short vol %
3%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
34.5K
Value
$350.0K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
53.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 13, 2026
This year
9

Amanat Acquisition Corp. agreed to combine with Corxel Pharmaceuticals, with closing expected in the first half of 2027. Management reported a $1,510,880 net loss from January 13, 2026 through September 30, 2026 and substantial doubt about its ability to continue as a going concern.

View
Earnings & Events
Investor Relations
Latest news
Corxel US and Amanat Acquisition…
Published
Oct 26, 2026
View

Performance

5D 20D 120D MTD YTD
AMAN -0.2% -1.5% -0.3% +0.0% —
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +5.3% +4.8% +5.3% +5.3% —
Key facts CIK 2112457 CUSIP G0375M101 13F (30d) 24 filings 24 filers Visit website Investor relations